Argatroban Injection News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Argatroban injection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Argatroban Injection Today - Breaking & Trending Today

Caplin Steriles receives final USFDA approval for Argatroban Injection

Caplin Point Laboratories announced that its subsidiary, Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application
(ANDA) Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single-dose vial presentation, a generic therapeutic equivalent version of (RLD), ARGATROBAN INJECTION, of Hikma Pharmaceuticals.
Caplin has received a CGT (Competitive Generic Therapies) Grant for this ANDA and Caplin is the first approved applicant for such competitive generic therapy, as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act.
Therefore, with this approval, Caplin is eligible for 180 days of CGT exclusivity for Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single- Dose Vial, under section 505(j)(5)(B)(v) of the FD&C Act. ....

United States , Caplin Steriles , Drug Administration , Hikma Pharmaceuticals , Caplin Point Laboratories , United States Food , Abbreviated New Drug Application , Argatroban Injection , Competitive Generic Therapies , Capital Market , Clinical Medicine , Medical Signs , Direct Thrombin Inhibitors , Heparin Induced Thrombocytopenia , Kims Health , Heparin Induced , ஒன்றுபட்டது மாநிலங்களில் , ஹிக்மா மருந்துகள் , கேப்ளின் பாயஂட் ஆய்வகங்கள் , ஒன்றுபட்டது மாநிலங்களில் உணவு , போட்டி ஜெநெரிக் சிகிச்சைகள் , மூலதனம் சந்தை , மருத்துவ மருந்து , மருத்துவ அறிகுறிகள் , இம்‌ஸ் ஆரோக்கியம் ,

Caplin Steriles gets USFDA approval for Argatroban Injection

Caplin Steriles gets USFDA approval for Argatroban Injection
Posted On:
2021-01-22 01:05:29
(Time Zone: Arizona, USA)
Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single-dose vial presentation, a generic therapeutic equivalent version of (RLD), ARGATROBAN INJECTION, of Hikma Pharmaceuticals Limited.
Caplin has received a CGT (Competitive Generic Therapies) Grant for this ANDA and Caplin is the first approved applicant for such competitive generic therapy, as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act. Therefore, with this approval, Caplin is eligible for 180 days of CGT exclusivity for Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single-Dose V ....

United States , Caplin Steriles , Caplin Point Laboratories Limited , Caplin Point Laboratories , Subsidiary Company Of Caplin Point Laboratories , Drug Administration , Caplin Steriles Limited , Hikma Pharmaceuticals , Time Zone , Point Laboratories Limited , Subsidiary Company , United States Food , Abbreviated New Drug Application , Argatroban Injection , Competitive Generic Therapies , Single Dose Vial , Mutual Funds , New Issue , Public Issue , Rights Issue , Stock Markets , Post Office , National Savings Scheme , Kisan Vikas Patra , Public Provident Fund , Goi Senior Citizens Savings Scheme ,